tbuckley/cabot-search huggingface dataset:
Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS
Authors: Koichi Takahashi, Feng Wang, Seth Sahil, Jianhua Zhang, Curtis Gumbs, Ghayas C. Issa, Christopher B. Benton, Sherry Pierce, Elias Jabbour, Naval Daver, Tapan Kadia, Courtney DiNardo, Hagop M. Kantarjian, Andrew Futreal, Guillermo Garcia-Manero
Journal: Blood (2015)
Costs of Inpatient Medications: Do Dispensing and Nursing Fees Lead to Overestimates?
Authors: Thomas E. MacMillan, Rodrigo B. Cavalcanti
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Inpatient Service Change
Authors: Vineet M. Arora, Jeanne M. Farnan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study
Authors: Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, Thomas Wolff, Karin Mayer, Joerg Chromik, Markus Radsak, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie, Aristoteles Giagounidis
Journal: Blood (2016)
Regulation of Erythropoiesis by Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin A (DZNep)
Authors: Tohru Fujiwara, Haruka Saitoh, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae
Journal: Blood (2012)
Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant
Authors: Tatyana Feldman, Anthony R Mato, Michele L. Donato, Scott D Rowley, Stuart L. Goldberg, Carolanne Carini, Marisa Valentinetti, Judith Smith, Gabriella Gadaleta, Coleen Bejot, Susan Stives, Mary Timberg, Ewelina A Protomastro, Joshua R. Richter, David H. Vesole, Andrew L Pecora, David S. Siegel, Andre Goy
Journal: Blood (2012)
Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).
Authors: Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Enrique Romaguera, Maria Alma Rodriguez, Felipe Samaniego, Peter McLaughlin, Frederick Hagemeister, Sattva Neelapu, Donald Podoloff, Barry Samuels, Evelyne Loyer, Yuhong Zhou, Anas Younes
Journal: Blood (2006)
Variable expression of somatostatin receptor type 2 in metastatic midgut carcinoid.
Authors: Eric H. Liu, Frank Revetta, Nipun B. Merchant, Mary Kay Washington, Chanjuan Shi
Journal: Journal of Clinical Oncology (2012)

189 Background: Somatostatin receptor type 2 (SSTR2) is frequently highly expressed in carcinoid tumors of the midgut. The presence of the receptor is the basis of imaging and therapeutics. Because of the high dependence of clinical care on SSTR2, we evaluated the immunohistochemical staining of specimens and correlated with clinical parameters. Methods: A tissue microarray (TMA) of 1 mm cores from paraffin embedded specimens of surgically resected midgut carcinoid were created with primary, lymph node, and liver metastatic lesions. These sections were stained by immunohistochemistry with anti-SSTR2 antibody, and scored on staining intensity. Sections were evaluated by membrane (0-none, 1 – weak, 2 – partial, 3- complete) and cytoplasmic (strong vs. weak) staining. Results: Thirty-five patient samples were included in the TMA. There were a total of 62 cores embedded: 21 primary lesions, 26 lymph node metastases, and 15 liver metastases. The total disease burden was captured in 17 patients, and specimens from all three sites were captured in 6 patients. Of the thirty-five patients, 6 had consistently weak SSTR2 staining (17% either 0 or 1). One of these cases had an intermediate grade tumor with Ki67 &gt;20%. Of the patients where more than one location was captured, 19/21 (90%) had consistent SSTR2 staining at all sites. Most cases had strong staining in the membrane (69%) while a minority had strong cytoplasmic staining (31%). Of the patients with weak SSTR2 membrane staining, 2 still had positive octreoscans. Clinically, most patients had good outcomes and 94% are still alive. Eight cases had carcinoid carcinomatosis (23%). Of the six with weak membrane staining, three had carcinomatosis (50%), while only 5/30 (17%) with strong membrane staining had carcinomatosis. Conclusions: While the majority of small bowel carcinoids and their metastatic lesions have strong SSTR2 staining, not all do. However, even in cases with low amounts of SSTR2 on the membrane, the tumors can still be detected on octreoscan, demonstrating the effect of receptor turnover. The loss of SSTR2 may be associated with more advanced disease, but is not completely predictive.
DAB<sub>389</sub> EGF for the treatment of superficial urothelial cancer.
Authors: T. W. Flaig, L. Su, A. Thorburn, A. E. Frankel, Y. Li, J. H. Woo, M. Varella-Garcia, F. G. La Rosa, C. Li, X. Yang
Journal: Journal of Clinical Oncology (2011)

255 Background: Intravesical BCG has remained the standard treatment for superficial bladder cancer for decades, despite frequent recurrences after its use. Toxic fusion proteins are a novel class of agents containing both a targeting and a treatment component; correspondingly, DAB 389 EGF contains an EGF and a diphtheria element, thereby targeting any cell expressing EGFR. Notably, the normal urothelium has little or no luminal EGFR expression in contrast to urothelial cancers, which frequently overexpress EGFR. Methods: DAB 389 EGF was tested in vitro to determine the effect of DAB 389 EGF on cell viability in culture. Tests of clonogenicity were performed by treating plated cells for 2 hours and following colony counts over 14 days. DAB 389 EGF was tested in an orthotopic murine model of bladder cancer with implanted HTB9 cells modified to express luciferase. DAB 389 EGF was administered intravesically via catheterization of the murine bladder and held in place for 2 hours with a temporary suture to close the urethra. Treatments were continued twice weekly for 2 weeks, with DT-GMCSF used as a control. Results: Treatment with DAB 389 EGF yielded IC50's ranging from 0.5 to 15.7 ng/ml in 8 tested bladder cancer cell lines, but the IC50 was &gt; 500ng/ml in the EGFR- negative H520 control cell line. A single 2-hour exposure to DAB 389 EGF (50ng/ml) decreased colony formation in all of the bladder cancer cell lines, with complete suppression in HT1376 and T24 cells. In the animal model, luciferase activity was lost in 5 of 6 mice treated with DAB 389 EGF, versus 1 of 6 mice treated with control. After the 2 week treatment period, histological assessment of the treated mice was undertaken and was consistent with the luciferase findings. FISH was used to detect human or murine-originated cells in order to confirm the presence or absence of xenograft tissue histologically. Conclusions: Targeted-toxin fusion proteins represent a novel treatment approach for superficial bladder cancer. By capitalizing on the differential expression of EGFR between cancerous and normal urothelium, DAB 389 EGF selectively targets bladder cancer cells. Preliminary animal studies support the efficacy and tolerability of this approach with additionally animal work currently underway. No significant financial relationships to disclose.
Effect of soft tissue sealer/divider in malignant soft tissue tumor surgery.
Authors: N. Yamamoto, H. Yasutake, H. Tsuchiya
Journal: Journal of Clinical Oncology (2011)

e20517 Background: In malignant bone and soft tissue tumor surgery, wide excision is standard and muscle resection is necessary. Most patients with malignant tumors have anemia and the need to control bleeding is important to decrease the chance of blood transfusion. Moreover, postoperative effusion into the operative dead space is a cause of postoperative infection. In this study, we evaluated the LigaSure Atlas soft tissue sealer/divider for its effects on bleeding in muscle resections in malignant soft tissue tumor surgery. Methods: We analyzed 22 cases of malignant soft tissue tumors in the thighs of patients who underwent tumor resection. Eleven cases were done with the LigaSure Atlas sealer/divider (LSA group), and 11 cases done without it (control group). The LSA group comprised 7 males and 4 females, with a mean age of 60.6 years, while the control group comprised 8 males and 3 females, with a mean age of 61.8 years. Results: The mean postoperative bleeding volumes were 226.6 ml in the LSA group and 704.1 ml in the control group. No blood transfusions were required in the LSA group, but blood transfusions were needed in two cases in the control group. Postoperative effusion into the operative dead space was observed in 5 cases of the control group, but none in the LSA group. Conclusions: LigaSure Atlas is significantly effective in control bleeding and effusion in muscle resection in malignant soft tissue tumor surgery.
Relationship between the loss of the retinoblastoma tumor suppressor and radiosensitivity.
Authors: R. B. Den, S. Ciment, A. Sharma, H. Mellert, S. Mc-Mahon, A. Dicker, K. E. Knudsen
Journal: Journal of Clinical Oncology (2011)

34 Background: Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer death in U.S. men. The retinoblastoma tumor suppressor protein, RB, plays a critical role in cell cycle regulation. Loss of RB has been observed in 25–30% of prostate cancers and is correlated with increasing tumor stage and grade. The clinical consequences of RB loss are unknown. We have previously shown that RB loss results in a castrate resistant phenotype. We hypothesized that RB loss would downregulate the G1-S cell cycle arrest normally induced by irradiation, inhibit DNA repair, and subsequently sensitize cells to mitotic catastrophe. Methods: Experimental work was performed with multiple isogenic prostate cancer cell lines (hormone sensitive: LNCaP and LAP-C4 cells and hormone resistant C42 cells; stable knockdown of RB using shRNA). Gamma H2AX assays were used to quantitate DNA damage and PARP cleavage and Caspase 3 were used to quantitate apoptosis. FACS analysis with BrdU was used to assess the cell cycle. Cell survival was measured using the clonogenic cell survival assay. In vivo work was performed in nude mice with tumor xenografts. Results: We observed that loss of RB increased radioresponsiveness in both transient and clonogenic cell survival assays in all cell lines (p&lt;0.05). Cell death was not mediated through increased apoptosis, however, there was increased cell cycling despite the presence of DNA damage in the RB knockdown cells. In vivo xenografts of the RB deficient tumors exhibited diminished tumor mass, lower PSA kinetics and decreased tumor growth after treatment with single fraction of ionizing radiation in comparison to RB intact tumors (p&lt;0.05). Conclusions: Loss of RB results in a differential response to ionizing radiation. Isogenic cells with RB knockdown are more sensitive to DNA damage and result in reduced cell survival. RB status is integral to determining which therapeutic modality should be employed in the management of prostate cancer. No significant financial relationships to disclose.
Preliminary results of a prospective trial of image-guided 3D conformal accelerated partial breast irradiation (APBI).
Authors: H. T. Pham, M. Yao, G. Song, K. R. Badiozamani, C. Salcedo - Wasicek, D. Wechter
Journal: Journal of Clinical Oncology (2011)

125 Background: External beam APBI is noninvasive and may offer better coverage of tumor sites in proximity to skin or chest wall than brachytherapy. To improve conformality and accuracy of treatment, we conducted a prospective IRB-approved clinical trial of APBI with implanted gold markers for image guidance. Cosmetic assessments through patient and physician questionnaires were collected. Adverse events were graded according to Common Terminology Criteria for Adverse Events v3.0. This is our preliminary report on toxicity and cosmetic outcomes. Methods: Thirty-four pts were enrolled from 12/06 to 4/10. Eligibility criteria included age &gt; 40, unifocal disease, ductal histology, tumor ≤ 3 cm, surgical margin ≥ 2 mm, and planning target volume: breast volume ratio &lt; 0.2. Vascular invasion, positive axillary nodes, high-grade ductal carcinoma in situ, and extensive intraductal component were excluded. Three gold fiducials were sutured into the operative site at the time of partial mastectomy. The clinical target volume comprised the surgical cavity including all surgical clips and gold fiducials + 10-15 mm. Prescribed dose was 3.85 Gy b.i.d. to 38.5 Gy, using 4–5 non-coplanar beams. Special breathing technique and image guidance with electronic portal imaging were used. Results: Median follow-up is 18 months (range 7-47 months). Most pts had mild acute reactions with only 6% grade 2 erythema. Late toxicities include hyperpigmentation (71% grade 1), fibrosis (26% grade 1, 32% grade 2), skin dimpling or indentation (38% grade 1, 3% grade 2), telangiectasias (12% grade 1), rib fractures in the treatment area (3% grade 2). The only grade 3 toxicity was a seroma requiring surgical excision in one pt. Cosmesis was rated by the pt versus (v.) physician as excellent/good in 85% v. 94%, 80% v. 90%, and 84% v. 85% of the pts at prior to treatment, 6 months, and one year respectively. Ninety-one percent of patients were “totally satisfied with the treatment and results.” No breast recurrences have been observed. Conclusions: Image-guided APBI is well-tolerated, with high patient satisfaction. Early cosmesis results, as assessed by both pts and physicians, are comparable to whole-breast radiotherapy.
Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.
Authors: Shaun P. Tolan, John Thoms, Alan Dal Pra, Omer Ahmed, Peter W. M. Chung, Fiona Warde, Alexandre Zlotta, Andrew Evans, Robert Glen Bristow, Michael Milosevic
Journal: Journal of Clinical Oncology (2012)

292 Background: Hypoxia may influence clinical outcomes in many human tumors, including muscle invasive urothelial carcinoma (UC) of the bladder. Hypoxia inducible factor-1 (HIF1), glucose transporter protein-1 (GLUT1) and carbonic anhydrase IX (CAIX) are all upregulated by hypoxia. This study examined the relationship between biomarkers of hypoxia or proliferation (Ki67) and clinical outcome in UC patients treated with radiotherapy (RT). Methods: 70 patients were treated with curative intent using RT alone or RT plus neoadjuvant or concurrent chemotherapy (RTCT) between 1997 and 2006. Archived, paraffin-embedded, transurethral biopsy material was available for 44 patients (35 men and 9 women). Tumor was clinically confined to the bladder wall (cT2) in 28 patients and involved perivesical tissues or adjacent organs (cT3/T4) in 16. Tissue micro-arrays were constructed and immunohistochemical analyses performed to assess biomarker expression, which was scored independently by 3 observers in a semi-quantitative manner. The biomarker scores were correlated with clinico-pathologic data extracted from the medical record and with patient outcome. Median follow-up was 4.2 years. Results: HIF1, GLUT1 and CAIX expression was seen in 43%, 96% and 65% of tumors respectively. The median Ki67 expression was 60%. There were no correlations between biomarkers expression and clinico-pathologic prognostic factors. The cystoscopic complete response rate was 71% at 2-3 months post-RT. The 4-year actuarial local control (LC) and overall survival (OS) rates were 48% and 55% respectively. High Ki67 expression was strongly predictive of better LC by univariate and multivariate analyses (70% vs 20% at 4 years, HR 0.95, p= 0.002), whereas no hypoxic marker predicted LC. High CAIX expression was predictive of inferior OS by multivariate analysis (HR 1.6, p=0.04). Conclusions: Tumor hypoxia influences the outcome of patients with bladder cancer treated with RT or RTCT and is a potential therapeutic target. High Ki67 has been reported previously to be a marker of sustained LC in the bladder following RTCT but the biologic mechanism underlying this association is unknown and requires further investigation.
Impact of primary Gleason grade 4 on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Authors: T. Saika, T. Uesugi, K. Edamura, M. Kobuke, H. Nose, S. Ebara, Y. Nasu, N. Katayama, H. Yanai, H. Kumon
Journal: Journal of Clinical Oncology (2011)

77 Background: To reveal a predictive factor for biochemical recurrence (BCR) after permanent prostate brachytherapy (PPB) using iodine-125 (125I) seed implantation in patients with localized prostate cancer classified as low or intermediate risk based on the National Comprehensive Cancer Network (NCCN) guidelines. Methods: From January 2004 to December 2009, consecutive 418 Japanese patients with clinically localized prostate cancer classified as low or intermediate risk based on the National Comprehensive Cancer Network (NCCN) guidelines were treated by PPB. The clinical factors including pathological data reviewed by central pathologist and follow-up data were prospectively collected. Kaplan-Meier and Cox regression analyses were used to assess the factors associated with BCR. Results: Median follow-up was 36.0 months. The 2, 3, 4 and 5-year BCR free rates using Phoenix definition were 98.3%, 96.0%, 91.6% and 87.0% respectively. On univariate analysis, primary Gleason grade 4 in biopsy specimen was strong predicting factor (p&lt;0.0001), while Gleason sum, age, initial PSA, initial PSA density, T stage and D90 were insignificant factors. Multivariate analysis indicated that primary Gleason grade 4 was most powerful prognostic factor associated with BCR (hazard ratio=10.101, 95% IC 3.080-33.126, p=0.0001). Conclusions: The primary Gleason grade 4 carried a worse BCR than the primary grade 3 in Gleason score 7 prostate cancer. Therefore, the indication for PPB in patients with Gleason sum 4+3 should deserve careful and thoughtful consideration. No significant financial relationships to disclose.
Predicting intrafraction displacement of the prostate during a five-fraction radiotherapy regimen: Implications for stereotactic body radiotherapy.
Authors: H. C. Quon, D. A. Loblaw, P. Cheung, A. Cesta, L. Holden, C. I. Tang, G. Pang, G. Morton, A. Mamedov, A. Deabreu
Journal: Journal of Clinical Oncology (2011)

90 Background: Accurate characterization of prostate displacement during stereotactic body radiotherapy (RT) may help optimize margins to maximize complication and disease-free survival. Also, if individual patients with large intrafraction displacement can be identified, additional interventions can be undertaken. Methods: Fifty-three men treated on a phase I/II study of extreme hypofractionation were selected for the study. A total dose of 35 Gy in 5 fractions was delivered with intensity modulated radiotherapy (IMRT). Daily image guidance was performed using gold seed fiducials. Position verification was obtained with orthogonal electronic portal images taken immediately before and after each fraction. Prostate shifts were recorded in 3 dimensions. Results: The mean intrafraction prostate displacements were -0.03 ± 0.61 mm (1SD), 0.21 ± 1.50 mm, and -0.86 ± 1.73 mm in the lateral, superior-inferior, and anterior-posterior directions, respectively. The mean intrafraction displacement during the first two fractions is moderately correlated with the displacement in the remaining 3 fractions, with correlation coefficients of 0.63 and 0.47 in the SI and AP directions, respectively. Conclusions: The mean intrafraction prostate displacement during a course of extreme hypofractionated radiotherapy is small. A strategy using the first two fractions to predict future displacements &gt;5mm shows promise and warrants further validation. No significant financial relationships to disclose.
Cardiometabolic Risks Among Survivors of Childhood Hematologic Malignancies.
Authors: Daniel A. Mulrooney, Aaron Kelly, K. Scott Baker, Lyn Steffen, Jill Lunsford-Lee, Anna Petryk, Alan R. Sinaiko, Donald R. Dengel, Joanna Perkins, Yoav H. Messinger, Xia Zhou, Julia Steinberger
Journal: Blood (2009)
Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs
Authors: Lurdes Zamora, Marta Cabezon, Olga Garcia, Esther Alonso, Silvia Marce, Cristalina Fernandez, Blanca Xicoy, Dolors Vela, Luz San Miguel, Imma Portal, Marisol Xandri, Joan Buch, Lluis Rodriguez, Diana Dominguez, Natividad Lopez, Isabel Granada, Esther Plensa, Neus Ruiz-Xivillé, Jose-Tomas Navarro, Concha Boqué, David Gallardo, Josep-Maria Ribera, Evarist Feliu, Fuensanta Millá
Journal: Blood (2012)